Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
2245903
Reference Type
Journal Article
Title
PREVENTION OF TOLERANCE TO HEMODYNAMIC-EFFECTS OF NITRATES WITH CONCOMITANT USE OF HYDRALAZINE IN PATIENTS WITH CHRONIC HEART-FAILURE
Author(s)
Gogia, H; Mehra, A; Parikh, S; Raman, M; Ajituppal, J; Johnson, JV; Elkayam, U
Year
1995
Is Peer Reviewed?
Yes
Journal
Journal of the American College of Cardiology
ISSN:
0735-1097
EISSN:
1558-3597
Volume
26
Issue
7
Page Numbers
1575-1580
Language
English
PMID
7594088
DOI
10.1016/0735-1097(95)00368-1
Web of Science Id
WOS:A1995TH12400002
Abstract
OBJECTIVES:
This study was designed to determine the effect of oral hydralazine on the development of nitrate tolerance in patients with chronic congestive heart failure.
BACKGROUND:
Early development of nitrate tolerance with either continuous administration of intravenous or topical nitrate preparations or frequent dosing of oral nitrates leads to significant attenuation of nitrate-mediated hemodynamic and anti-ischemic effects. In recent animal experiments, prevention of nitroglycerin-induced hemodynamic tolerance with a concomitant use of hydralazine was demonstrated. This finding may have important clinical relevance.
METHODS:
Twenty-eight patients with chronic heart failure due to left ventricular systolic dysfunction were randomized to receive either a continuous infusion (24 h) of nitroglycerin alone (group I, 14 patients) or concomitantly with oral hydralazine (75 mg four times a day [group II, 14 patients]). The effect of nitroglycerin in each group was evaluated by analysis of variance for repeated measures. The power of the analysis to detect a 5.4-mm Hg (20%) change in mean pulmonary artery wedge pressure was 90%.
RESULTS:
Baseline hemodynamic variables as well as the initial hemodynamic response to nitroglycerin were comparable in both groups. Compared with the initial response to nitroglycerin, a significant attenuation of effect was found in group I at 24 h in mean (+/- SE) pulmonary artery pressure (27 +/- 4% vs. 10 +/- 3%, p < 0.05) and mean pulmonary artery wedge pressure (40 +/- 4% vs. 16 +/- 4%, p < 0.05). In group II, conversely, oral hydralazine prevented nitroglycerin-induced hemodynamic tolerance and resulted in a persistent effect on mean pulmonary artery and wedge pressures throughout the study period (31 +/- 3% vs. 27 +/- 4%, p = 0.13 and 37 +/- 4% vs. 34 +/- 6%, p = 0.40, respectively). In addition, the initial effect on blood pressure was attenuated at 24 h in group I (5 +/- 2% vs. 12 +/- 3%, p < 0.05) but not in group II (15 +/- 3% vs. 17 +/- 2%, p = 0.46).
CONCLUSIONS:
In patients with chronic heart failure due to left ventricular systolic dysfunction, the concomitant use of oral hydralazine prevents early development of nitrate tolerance and results in a persistent nitrate-mediated hemodynamic effect on systemic and pulmonary artery and left ventricular filling pressures. These data may support the concurrent use of hydralazine in patients with heart failure treated with organic nitrates.
Tags
IRIS
•
Nitrate/Nitrite
Supplemental LitSearch Update 1600-2015
PubMed
WoS
New to project
PFAS
•
PFAS Universe
Data Source
Web of Science
Pubmed
Oxybis((difluoromethoxy)difluoromethane)
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity